$94 B

BMY Mkt cap, 15-Oct-2018

$10.9 B

Bristol-Myers Squibb Revenue Q2, 2018
Bristol-Myers Squibb Gross profit (Q2, 2018)7.7 B
Bristol-Myers Squibb Gross profit margin (Q2, 2018), %70.6%
Bristol-Myers Squibb Net income (Q2, 2018)1.9 B
Bristol-Myers Squibb Cash, 30-Jun-20185 B
Bristol-Myers Squibb EV94.7 B

Bristol-Myers Squibb Revenue

Bristol-Myers Squibb revenue was $19.43 b in FY, 2016 which is a 17.3% year over year increase from the previous period.

Embed Graph

Bristol-Myers Squibb Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

16.4b15.9b16.6b19.4b

Revenue growth, %

(3%)4%17%

Cost of goods sold

4.6b3.9b3.9b4.9b

Gross profit

11.8b11.9b12.7b14.5b

Gross profit Margin, %

72%75%76%75%

Pre tax profit

2.9b2.4b2.1b5.9b

Income tax expense

311.0m352.0m446.0m1.4b

Net Income

2.6b2.0b1.6b4.5b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

4.1b3.8b3.9b3.9b4.0b4.2b4.1b4.4b4.9b4.9b4.9b5.1b5.3b5.2b10.9b

Cost of goods sold

1.2b968.0m991.0m1.0b847.0m1.0b1.1b1.1b1.2b1.3b1.3b1.6b1.6b1.6b3.2b

Gross profit

2.9b2.8b2.9b2.9b3.2b3.2b3.0b3.3b3.7b3.6b3.7b3.6b3.7b3.6b7.7b

Gross profit Margin, %

71%75%75%74%79%76%73%76%75%73%74%70%70%69%71%

R&D expense

893.0m946.0m1.4b983.0m1.0b1.9b1.1b1.1b1.3b1.1b1.3b1.7b1.5b1.3b3.7b

Operating expense total

3.2b2.8b3.4b2.9b2.6b4.1b3.1b2.7b3.3b3.4b3.0b3.8b4.1b3.4b8.6b

Pre tax profit

985.0m448.0m1.0b1.4b52.0m987.0m1.7b1.6b1.6b2.0b1.3b1.2b1.8b2.3b

Income tax expense

49.0m114.0m276.0m249.0m162.0m257.0m449.0m427.0m344.0m429.0m373.0m327.0m284.0m419.0m

Net Income

936.0m334.0m732.0m1.2b730.0m1.2b1.2b1.5b922.0m856.0m1.5b1.9b

Bristol-Myers Squibb Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.6b5.6b2.4b4.2b

Inventories

1.5b1.6b1.2b1.2b

Current Assets

18.9b14.6b10.4b13.7b

Goodwill

7.1b7.0b6.9b6.9b

Total Assets

38.6b33.7b31.7b33.7b

Accounts Payable

2.6b2.5b1.6b1.7b

Dividends Payable

634.0m645.0m655.0m

Short-term debt

359.0m590.0m139.0m992.0m

Current Liabilities

12.4b8.5b8.0b8.8b

Long-term debt

8.0b7.2b6.6b5.7b

Total Debt

8.3b7.8b6.7b6.7b

Retained Earnings

33.0b32.5b31.6b33.5b

Total Equity

15.2b15.0b14.4b16.3b

Debt to Equity Ratio

0.5 x0.5 x0.5 x0.4 x

Debt to Assets Ratio

0.2 x0.2 x0.2 x0.2 x

Financial Leverage

2.5 x2.3 x2.2 x2.1 x

Quarterly

USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

4.2b4.0b2.6b2.9b3.4b3.9b3.5b4.6b5.3b5.0b

Accounts Receivable

5.7b5.6b

Inventories

1.3b1.1b1.3b1.4b1.5b1.4b1.2b1.3b1.2b1.2b

Current Assets

13.1b12.9b11.2b12.3b13.2b13.6b14.3b15.0b14.6b13.9b

Goodwill

7.0b7.0b6.9b6.9b6.9b6.9b6.9b6.9b6.9b6.7b

Total Assets

32.0b31.8b31.9b32.8b33.7b32.9b33.4b34.0b33.1b32.6b

Accounts Payable

1.8b1.2b1.5b1.5b1.4b1.5b1.6b1.7b1.7b1.9b

Dividends Payable

634.0m636.0m

Short-term debt

755.0m642.0m106.0m155.0m990.0m

Current Liabilities

7.4b7.2b7.6b7.9b9.0b8.5b9.0b9.4b9.6b9.9b

Long-term debt

6.6b6.6b6.6b6.6b5.8b7.2b6.9b7.0b5.8b5.7b

Total Debt

7.4b7.3b6.7b6.7b6.8b7.2b6.9b7.0b5.8b5.7b

Total Liabilities

16.7b16.5b17.3b17.8b17.9b18.4b18.6b19.1b20.2b20.2b

Common Stock

221.0m221.0m221.0m221.0m221.0m

Retained Earnings

32.4b32.4b32.2b32.7b33.3b33.7b33.9b34.1b32.3b32.0b

Total Equity

15.3b15.3b14.6b15.1b15.8b14.5b14.8b14.9b12.9b12.4b

Financial Leverage

2.1 x2.1 x2.2 x2.2 x2.1 x2.3 x2.3 x2.3 x2.6 x2.6 x

Bristol-Myers Squibb Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

2.6b2.0b1.6b4.5b

Inventories

(45.0m)(254.0m)97.0m(152.0m)

Accounts Payable

412.0m(44.0m)(919.0m)104.0m

Cash From Operating Activities

3.5b3.1b1.8b2.9b

Cash From Investing Activities

(572.0m)1.2b(1.6b)1.5b

Long-term Borrowings

(597.0m)(676.0m)(2.0b)(15.0m)

Cash From Financing Activities

(1.1b)(2.4b)(3.4b)(2.4b)

Free Cash Flow

2.7b4.1b

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

1.8b936.0m1.3b2.0b1.2b1.1b1.8b1.2b2.4b3.6b1.5b2.4b3.3b1.5b1.9b

Accounts Receivable

219.0m112.0m

Inventories

(8.0m)(144.0m)(157.0m)(162.0m)51.0m162.0m231.0m(44.0m)(111.0m)(107.0m)(71.0m)(58.0m)7.0m(4.0m)(122.0m)

Accounts Payable

301.0m(12.0m)(112.0m)63.0m(83.0m)(618.0m)(1.2b)(77.0m)(36.0m)(142.0m)(114.0m)(85.0m)63.0m(241.0m)(101.0m)

Cash From Operating Activities

2.1b1.7b2.6b626.0m697.0m1.2b25.0m1.4b2.4b4.2b1.2b2.2b

Cash From Investing Activities

(257.0m)2.2b701.0m865.0m754.0m(526.0m)(588.0m)1.4b1.8b1.5b(203.0m)(1.2b)(1.1b)(43.0m)(391.0m)

Long-term Borrowings

(676.0m)(676.0m)(676.0m)(676.0m)(2.0b)(2.0b)(2.0b)(2.0b)(474.0m)(1.2b)(5.0m)

Cash From Financing Activities

(1.8b)(1.2b)(1.7b)(2.2b)(682.0m)(1.6b)(2.3b)(792.0m)(1.3b)(1.9b)(1.0b)(2.0b)(2.7b)(1.2b)(2.2b)

Free Cash Flow

(478.0m)578.0m1.9b3.4b936.0m1.8b

Bristol-Myers Squibb Ratios

USDY, 2018

EV/CFO

42.4 x

EV/FCF

52.7 x

Financial Leverage

2.6 x
Report incorrect company information

Bristol-Myers Squibb Operating Metrics

FY, 2015FY, 2016

Phase III Trials Products

2 8

Projects in R&D Pipeline

32 44
Report incorrect company information